Hypogonadism is common in men with myopathies

Journal of Clinical Neuromuscular Disease

Volumn 9, Issue 4, 2008, Pages 397-401

  Al Harbi, Talal M ^a   Bainbridge, Laura J ^a   McQueen, Matthew J ^a   Tarnopolsky, Mark A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Androgen deficiency; Muscular dystrophy; Myopathy; Oxandrolone; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DYSTROPHINOPATHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; HUMAN; HYPOGONADISM; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; METABOLIC MYOPATHY; MUSCLE MASS; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; TESTOSTERONE BLOOD LEVEL; AGE DISTRIBUTION; BLOOD; CLASSIFICATION; COHORT ANALYSIS; MIDDLE AGED; MUSCLE DISEASE;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOSITIS, INCLUSION BODY; MYOTONIC DYSTROPHY; TESTOSTERONE;

EID: 50349085794     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e318176eb55     Document Type: Article

References (36)

1. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598.
2. Gray A, Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.
3. Perry HM III, Miller DK, Patrick P, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49:1085-1091.
4. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282: E601-E607.
5. Ferrando AA, Tipton KD, Doyle D, et al. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol. 1998; 275(pt 1):E864-E871.
6. Chauhan AK, Katiyar BC, Misra S, et al. Muscle dysfunction in male hypogonadism. Acta Neurol Scand. 1986;73:466-471.
7. Roy TA, Blackman MR, Harman SM, et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002;283:E284-E294.
8. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1-7.
9. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab. 1996;81:3469-3475.
10. Drucker WD, Rowland LP, Sterling K, et al. On the function of the endocrine glands in myotonic muscular dystrophy. Am J Med. 1961;31:941-950.
11. Vazquez JA, Pinies JA, Martul P, et al. Hypothalamic-pituitary-testicular function in 70 patients with myotonic dystrophy. J Endocrinol Invest. 1990;13: 375-379.
12. Drucker WD, Blanc WD, Rowland LP, et al. The testis in myotonic muscular dystrophy: a clinical and pathological study with a comparison with the Klinefelter syndrome. J Clin Endocrinol Metab. 1963;23:59-75.
13. Takeda R, Ueda M. Pituitary-gonadal function in male patients with myotonic dystrophy-serum luteinizing hormone, follicle stimulating hormone and testosterone levels and histological damage of the testis. Acta Endocrinol (Copenh). 1977;84:382-389.
14. Febres F, Scaglia H, Lisker R, et al. Hypothalamic-pituitary-gonadal function in patients with myotonic dystrophy. J Clin Endocrinol Metab. 1975;41: 833-840.
15. Brisson D, Houde G, St-Pierre J, et al. The pleiotropic expression of the myotonic dystrophy protein kinase gene illustrates the complex relationships between genetic, biological and clinical covariates of male aging. Aging Male. 2002;5:223-232.
16. Griggs RC, Halliday D, Kingston W, et al. Effect of testosterone on muscle protein synthesis in myo-tonic dystrophy. Ann Neurol. 1986;20:590-596.
17. Kingston WJ, Moxley RT III, Griggs RC. Effect of testosterone on whole body amino acid utilization in myotonic dystrophy. Metabolism. 1986;35: 928-932.
18. Griggs RC, Pandya S, Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989;39(pt 1):219-222.
19. Griggs RC, Kingston W, Herr BE, et al. Myotonic dystrophy: effect of testosterone on total body potassium and on creatinine excretion. Neurology. 1985;35:1035-1040.
20. Welle S, Jozefowicz R, Forbes G, et al. Effect of testosterone on metabolic rate and body composition in normal men and men with muscular dystrophy. J Clin Endocrinol Metab. 1992;74:332-335.
21. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
22. Harper P, Penny R, Foley TP, et al. Gonadal function in males with myotonic dystrophy. J Clin Endocrinol Metab. 1972;35:852-856.
23. Sagel J, Distiller LA, Morley JE, et al. Myotonia dystrophica: studies on gonadal function using luteinizing hormone-releasing hormone (LRH). J Clin Endocrinol Metab. 1975;40:1110-1113.
24. Mastrogiacomo I, Bonanni G, Menegazzo E, et al. Clinical and hormonal aspects of male hypogonad-ism in myotonic dystrophy. Ital J Neurol Sci. 1996; 17(1):59-65.
25. Lund BC, Bever-Stille KA, Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy. 1999;19:951-956.
26. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci. 2003;58:1002-1008.
27. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92:549-555.
28. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(Suppl 3):14-22.
29. Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14(2):119-125.
30. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647-2653.
31. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407-413.
32. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001; 56:1075-1079.
33. Wolf SE, Thomas SJ, Dasu MR, et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg. 2003;237:801-810.
34. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58:1081-1087.
35. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670-2677.
36. Juul A, Skakkebaek NE. Androgens and the ageing male. Hum Reprod Update. 2002;8:423-433.